Expanded Treatment Options for Recurrent Malaria

Two newer antimalarial combinations were noninferior to current first-line artemisinin-combination therapies in a large randomized trial in west Africa.

Treatment for recurrent malaria in west Africa is limited by a lack of data on the safety and efficacy of drug combination options. To address this issue, investigators conducted a randomized, longitudinal, noninferiority, phase IIIb/IV trial involving 4710 patients in Burkina Faso, Guinea, and Mali with uncomplicated, microscopically confirmed malaria. Patients with known HIV positivity, chronic hepatitis, or elevated liver enzymes were excluded.

Patients were assigned to receive a newer drug combination, either pyronaridine–artesunate (P-A) or dihydroartemisinin–piperaquine (D-P), or a currently used first-line therapy, either artesunate–amodiaquine (A-A) or artemether–lumefantrine (A-L). Treatment was weight-based and administered once or…

Reviewing Author

Mary E. Wilson, MD

Disclosures

Consultant/Advisory BoardOneHealthTrust (formerly Center for Disease Dynamics, Economics, and Policy); Global Health Institute, University of Wisconsin

RoyaltiesUpToDate

Editorial BoardsJournal of Travel Medicine

Mary E. Wilson, MD

Disclosures

Consultant/Advisory BoardOneHealthTrust (formerly Center for Disease Dynamics, Economics, and Policy); Global Health Institute, University of Wisconsin

RoyaltiesUpToDate

Editorial BoardsJournal of Travel Medicine

Expanded Treatment Options for Recurrent Malaria

Topics

Reviewing Author